Physician Views: What opportunity for Eylea in diabetic retinopathy?

With Regeneron Pharmaceuticals' Eylea having exited its imperious growth phase, the company is looking at opportunities to expand revenue for the franchise before competition intensifies. Most recently, Regeneron has been able to tout positive data from the Phase III PANORAMA trial in diabetic retinopathy; we are snap-polling US ophthalmologists to get a better understanding of how Eylea may be used in this indication…  

The Phase III PANORAMA trial met its primary endpoint with 58 percent of nonproliferative diabetic retinopathy (NPDR) patients who received treatment with Eylea (aflibercept) experiencing a two-step or greater improvement from baseline on the Diabetic Retinopathy Severity Scale (DRSS) at week 24, compared to 6 percent of patients receiving sham injection.

How compelling are these data?

Not compelling

Moderately compelling

Very compelling

Patients in the active treatment groups received on average 4.4 Eylea injections during the 24-week period. Assuming Eylea is approved in the future for the treatment of NPDR, would you expect its updated label to be practice changing in this indication?

No

Moderately so

Significantly so

Do you use Lucentis for the treatment of NPDR/PDR since its approval for this indication last year?

No

Moderate use

Significant use

Based on your current treatment practice and knowledge of emerging therapies in the various indications that Eylea is indicated for, how do you expect your utilisation of Eylea to evolve over the next five years?

Decline significantly

Decline moderately

Stay the same

Increase moderately

Increase significantly

In the future, how comfortable would you be using an FDA-approved biosimilar version of Eylea?

Not comfortable

Moderately comfortable

Very comfortable

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.